10-K: PharmaCyte Biotech Navigates Clinical Hold, Strategic Shifts

PharmaCyte Biotech reports a significant net income increase driven by investment gains, while facing ongoing FDA clinical hold challenges and strategic reevaluation of its core cancer therapy programs.

Summary

• PharmaCyte Biotech is a biotechnology company focused on developing cellular therapies for cancer, particularly locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC), using its proprietary Cell-in-a-Box encapsulation technology (CypCaps).
• The U.S. Food and Drug Administration (FDA) placed a clinical hold on the Investigational New Drug (IND) application for the LAPC clinical trial in October 2020, requesting additional sequencing data, stability studies, device compatibility evaluations, manufacturing process descriptions, product release specifications, comparability demonstrations, biocompatibility assessments, and an additional nonclinical animal study.
• A Strategic Scientific Committee was formed in November 2023 to review business risks, development programs, and the relationship with SG Austria, including concerns about expired licensed patents and sole reliance on SG Austria for know-how.
• Spending on development programs, including pre-clinical and clinical activities, has been curtailed pending the completion of the Scientific Committee's review and Board's determination of future actions.
• Reported a net income attributable to common stockholders of approximately $23,362,107 for the fiscal year ended April 30, 2025, a substantial improvement from a net loss of $17,237,403 in the prior year.
• This net income was primarily driven by a $21,395,734 gain on a related party investment in TNF Pharmaceuticals, Inc. and $14,100,000 in fair value fluctuations of warrant and derivative liabilities.
• Cash and cash equivalents decreased significantly from $50,179,968 as of April 30, 2024, to $15,172,163 as of April 30, 2025.
• Working capital also decreased from approximately $43,018,504 in 2024 to $19,500,954 in 2025.
• Total operating expenses decreased by $4,142,146 to $4,377,862 in 2025, mainly due to reductions in compensation, director fees, asset impairment, and legal/professional fees, despite a slight increase in R&D expenses.
• Research and development expenses increased to $438,416 in 2025 from $407,431 in 2024, attributed to agreements with consultants for pancreatic cancer research.
• The company entered into a $5,000,000 convertible note and warrant purchase agreement with Femasys Inc. in November 2023 and a $7,000,000 preferred stock and warrant purchase agreement with TNF Pharmaceuticals, Inc. in May 2024.
• A legal complaint with H.C. Wainwright & Co., LLC was settled for $1,550,000 in cash and the issuance of warrants to purchase 656,250 shares of common stock.
• Material weaknesses in internal controls over financial reporting were identified, specifically concerning insufficient segregation of duties for the Chief Financial Officer and inadequate management review controls.

Sentiment

Score: 4

Explanation: While the company reported a net income due to investment gains and fair value adjustments, its core business remains in a clinical hold with significant delays, declining cash reserves, and ongoing reliance on external funding for future development. The strategic reevaluation and dependence on third parties for critical technology and manufacturing also add uncertainty.

Positives

• Achieved a net income attributable to common stockholders of approximately $23.36 million for the year ended April 30, 2025, a significant turnaround from a $17.24 million net loss in the previous year.
• The net income was substantially boosted by a $21.40 million gain on a related party investment in TNF Pharmaceuticals, Inc. and $14.10 million in fair value fluctuations of warrant and derivative liabilities.
• Successfully completed all required product stability studies (3, 6, 9, 12, 18, and 24 months) for the pancreatic cancer product candidate, demonstrating its stability when stored frozen.
• Completed additional studies requested by the FDA, including a stability study on the cells from the Master Cell Bank.
• Successfully determined and confirmed the exact sequence of the cytochrome P450 2B1 gene, confirming the integrity and stability of the inserted genes.
• Completed eight out of ten requested biocompatibility studies successfully, indicating that the capsule material is bioinert and shows no evidence of toxicity.
• Received Orphan Drug Designation from both the FDA and the European Medicines Agency for the pancreatic cancer therapy, which provides potential market exclusivity and research and development tax credits.
• Increased authorized common stock shares from 133,333,334 to 200,000,000 in September 2023, providing greater flexibility for future equity financing.
• Received Nasdaq Stockholder Approval for the issuance of more than 19.9% of outstanding common stock related to the Series B Preferred Shares.
• The new Executive Compensation Agreement for Joshua N. Silverman provides a clear compensation structure and incentives for the Chief Executive Officer, President, and Executive Chairman.

Negatives

• The Investigational New Drug (IND) application for the LAPC clinical trial remains on clinical hold by the FDA since October 2020, causing significant delays and uncertainty for the company's primary development program.
• The company's dependence on SG Austria for its Cell-in-a-Box technology is a concern, as all licensed patents have expired and the know-how solely resides with SG Austria, leading to a reevaluation of the relationship.
• Spending on development programs, including pre-clinical and clinical activities, has been curtailed until the Strategic Scientific Committee and Board complete their review, further delaying progress.
• Cash and cash equivalents decreased substantially from $50,179,968 in 2024 to $15,172,163 in 2025, indicating significant cash burn.
• Working capital decreased from $43,018,504 in 2024 to $19,500,954 in 2025.
• The company has experienced negative operating cash flows since its inception and expects to continue incurring significant operating losses for the foreseeable future.
• No commercial revenue has been generated to date, and no product revenue is expected in the foreseeable future.
• Reliance on Austrianova as the sole source manufacturer for product candidates poses risks, as Austrianova has experienced supply chain delays and is believed to be experiencing liquidity issues.
• Identified material weaknesses in internal controls over financial reporting, specifically insufficient segregation of duties for the Chief Financial Officer and inadequate management review controls.
• The Femasys Series B Warrants, part of a $5 million investment, expired worthless on November 21, 2024.
• The company fully impaired its investment in SG Austria by approximately $1.6 million in 2024 due to SG Austria's financial position and viability concerns.
• A diabetes licensed asset technology was fully impaired by $2 million in 2024, as it was deemed not viable for insulin-producing cells and diabetes treatment.
• The market price of common stock experienced significant volatility, trading between a high of $2.42 and a low of $1.03 per share during the year ended April 30, 2025.
• No plans to pay dividends on common stock in the foreseeable future, and preferred share terms currently restrict dividend payments on common stock.

Risks

• Limited operating history and no products approved for clinical trials or commercial sale make it difficult to evaluate current business and predict future success and viability.
• The FDA clinical hold on the IND for LAPC may not be lifted, or may take considerable time and expense, which could materially harm business and prospects.
• Reliance on Austrianova for manufacturing product candidates increases the risk of insufficient quantities or unacceptable costs, potentially delaying, preventing, or impairing development or commercialization efforts.
• Disruptions in the global economy and supply chains may have a material adverse effect on business, financial condition, results of operations, and third-party partners.
• Inability to successfully raise sufficient additional capital could limit future clinical trials and product development, threatening long-term viability.
• Limited resources require prioritization of product candidates, potentially leading to expending resources on unsuccessful programs or failing to capitalize on more profitable opportunities.
• No commercial revenue and may never become profitable.
• Inability to obtain, or delays in obtaining, required regulatory approvals will prevent commercialization and materially impair revenue generation.
• U.S. regulatory agencies may not accept data from clinical trials conducted at sites outside of the U.S.
• Promising results in previous clinical trials for pancreatic cancer may not be replicated in future clinical trials, leading to development delays or failure to obtain marketing approval.
• Inability to protect intellectual property rights throughout the world, including the expiration of foundational licensed patents and reliance on trade secrets.
• Heavy reliance on third parties (CROs, clinical data management organizations, medical institutions, clinical investigators) to conduct preclinical studies and clinical trials, with risks of unsatisfactory performance or failure to meet deadlines.
• Future dilution may be experienced as a result of future equity offerings.
• Failure to comply with Nasdaq's continuing listing standards could lead to delisting, limiting investor transactions and subjecting the company to additional trading restrictions.
• Volatility in stock price may adversely affect the trading price of common stock.
• A large number of shares may be issued and subsequently sold upon the exercise of existing options and warrants and the conversion of preferred shares.
• As a smaller reporting company, the company complies with reduced disclosure requirements, which may make its common stock less attractive to investors.
• As a non-accelerated filer, the company is not required to comply with auditor attestation requirements of the Sarbanes-Oxley Act, which may negatively affect the trading price of its common stock.
• Risks related to owning securities issued by other public companies (Femasys, TNF), including potential losses if market prices are lower than conversion/exercise prices.
• Risk of being categorized as an investment company under the Investment Company Act of 1940 due to ownership of securities of other public companies.
• Significant management changes could increase control risks and have a material adverse effect on the ability to do business and results of operations.
• High dependence on the Chief Executive Officer and Chief Financial Officer, with future success dependent on their retention and the ability to attract other qualified personnel.
• Ability to use net operating loss carryforwards and certain other tax attributes may be limited due to past or future ownership changes and tax law changes.
• Difficulties in managing growth as development and regulatory capabilities expand, potentially disrupting operations.
• Business and operations would suffer in the event of system failures or cyberattacks, leading to disclosure of confidential information, damage to reputation, and significant financial/legal exposure.
• Legal, regulatory, financial, and other risks associated with international operations, including foreign currency fluctuations, political instability, and intellectual property protection challenges.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of any developed products.
• Increased costs due to operating as a public company and management devoting substantial time to new compliance initiatives.
• Uncertainty regarding the insurance coverage and reimbursement status of newly approved products could limit marketability and revenue generation.
• Employees, consultants, and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory standards, leading to significant liability and reputational harm.
• Transactions and relationships outside the U.S. are subject to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws, with potential for fines and sanctions for violations.
• Recently enacted and future legislation (e.g., Inflation Reduction Act, state prescription drug affordability boards) could increase the difficulty and cost of obtaining marketing approval and affect product pricing.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future as it advances research and development of its product candidates. Additional capital will be required to complete a clinical trial for pancreatic cancer, with future capital requirements being difficult to forecast and dependent on factors such as FDA approval, patient enrollment, and regulatory costs. Existing cash balances are projected to fund operating expenses for at least the next 12 months. The company is actively working to strengthen ties and interactions with related parties to mitigate risks and is evaluating the impact of new tax laws, with certain provisions of The One Big Beautiful Bill Act of 2025 becoming effective in fiscal 2026.

Management Comments

• "We believe that the expectations reflected in the forward-looking statements contained in this Report are reasonable, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements."
• "We believe that the prodrug/activator technology is well suited to address the shift from cure/enhanced survival to creating a zone of clearance around blood vessels adjacent to tumor. This zone of clearance improves the probability of successful surgical resection of LAPC, which has been shown to improve survival."
• "Our reevaluation for addressing the FDA concerns has resulted in delays stemming from the review of the non-clinical package provided by SG Austria and changes to the FDA review process."
• "Our scientific consultants have been in active dialog with the FDA seeking permission to forego the large animal study. The technology upon which the LAPC treatment will be based, intra-arterial chemotherapy, has been used in five clinical trials in humans. The data available from these human clinical trials supersedes large animal study data."
• "We are waiting for the FDAs responses and hope the FDA will accept that the LAPC treatment now meets manufacturing standard requirements, which have significantly improved since the clinical hold was first placed."
• "We are in ongoing dialogue with SG Austria to prepare for the next steps and add requested information to the drug master file upon which the Company still relies on."
• "We believe that our internal assumptions are reasonable, these assumptions involve the exercise of significant judgment on the part of our management, are inherently uncertain and the reasonableness of these assumptions has not been assessed by an independent source."
• "Management believes that the following accounting estimates are the most critical to aid in fully understanding and evaluating our reported financial results and require managements most difficult, subjective or complex judgments resulting from the need to make estimates about the effects of matters that are inherently uncertain."
• "Management does not believe that there are significant uncertain tax positions in the tax years 2024 and 2023."

Industry Context

The company operates in the highly competitive biotechnology and pharmaceutical industries, specifically targeting cancer therapy. Pancreatic cancer, the company's primary focus, is a growing concern in industrialized nations, with an estimated 64,000 diagnoses and 51,000 deaths in the U.S. in 2023, highlighting a significant unmet medical need for patients unresponsive to current treatments. The industry is characterized by intense competition from various players, including major pharmaceutical companies and academic institutions. The company's prodrug/activator technology aligns with a broader industry trend towards targeted therapies that create a 'zone of clearance' to improve surgical resection outcomes. Regulatory frameworks, such as the Biologics Price Competition and Innovation Act (BPCIA) and Orphan Drug designations, are crucial for market entry and exclusivity. The industry also faces increasing governmental scrutiny over drug pricing and cost containment measures, exemplified by the Inflation Reduction Act and state-level Prescription Drug Affordability Boards, which could impact future profitability and market access.

Comparison to Industry Standards

• The Cell-in-a-Box technology, utilizing cellulose-based capsules, is presented as having advantages over competitors' materials (e.g., alginate, collagen) due to its inherent strength, durability, bioinertness, and lack of immune response or degradation in the human body.
• The ability to cryopreserve encapsulated cells with approximately 85% viability after thawing is highlighted as a unique and superior feature compared to other cell encapsulation materials, enabling long-term storage and distant shipment.
• The company's prodrug/activator technology aims to optimize cancer killing with enhanced potency and limited exposure away from the target tumor, addressing a strategic shift in LAPC treatment towards improving surgical resection, which is a key area of innovation in oncology.
• Orphan Drug Designation from both the FDA and the European Medicines Agency provides a competitive advantage, offering market exclusivity and tax credits, which are standard incentives for developing treatments for rare diseases.
• The company acknowledges facing intense competition from entities with substantially greater financial and marketing resources, stronger brand recognition, and established customer/supplier relationships, a common challenge for smaller, early-stage biotechnology firms.

Management Changes

Corporate Governance

Legal Proceedings

• On May 16, 2025, the company entered into a settlement and release agreement with H.C. Wainwright & Co., LLC, resolving a complaint filed on December 4, 2023, alleging a breach of contract.
• The settlement required a payment of $1,550,000, consisting of an initial payment of $1,250,000 and twelve equal payments of $25,000.
• As part of the settlement, the company also issued warrants (First Warrant Issuance) to purchase 343,183 shares of common stock with an exercise price of $4.00 per share and a five-year term.
• The company elected to issue additional warrants (Additional Warrants) to purchase 313,067 shares of common stock with an exercise price of $4.00 per share and a five-year term, effective July 29, 2025, in lieu of a $226,254 cash payment.
• No other material legal proceedings are pending against the company or its officers/directors, and no such litigation is contemplated by governmental authorities.

Related Party Transactions

• The company owns 13.9% of the equity in SG Austria, which is reported on the cost method of accounting.
• The company did not purchase products and services from SG Austria's subsidiaries (Austrianova and Austrianova Thailand) in the years ended April 30, 2025, and 2024.
• A consulting agreement with Vin-de-Bona Trading Company Pte. Ltd., owned by Prof. Gnzburg and Dr. Salmons (officers of Austrianova), resulted in payments of approximately $16,000 in FY2025 and $5,000 in FY2024.
• Joshua Silverman, the company's Interim Chief Executive Officer, was appointed to the Femasys Inc. board of directors as part of the Femasys Transaction.
• Joshua Silverman, the company's Interim Chief Executive Officer, is chairman of TNF Pharmaceuticals, Inc.'s board of directors as part of the TNF Transaction.

Stakeholder Impact

• Shareholders face potential future dilution from equity offerings and continued stock price volatility. While the company reported net income, it was largely from non-operating gains, indicating ongoing operational challenges and reliance on external funding.
• Employees (currently two full-time) and consultants are critical to the company's R&D efforts, and the high dependence on key officers, coupled with management changes and internal control weaknesses, could affect operational stability.
• Patients, particularly those with LAPC, will experience continued delays in accessing potential new therapies due to the ongoing FDA clinical hold and the curtailment of development spending.
• Suppliers and creditors, especially Austrianova (the sole manufacturer), face risks related to supply chain disruptions and Austrianova's liquidity issues, which could impact the company's ability to produce product candidates.
• Regulatory bodies, particularly the FDA, are actively engaged with the company regarding the clinical hold, and the company's future depends on successfully addressing regulatory requirements.

Next Steps

• Complete the remaining studies and gather additional information requested by the FDA to lift the clinical hold on the LAPC IND.
• Continue active dialogue with the FDA, seeking permission to forego the large animal study.
• Prepare for a new clinical protocol for LAPC that reflects the standard of care.
• Complete the review by the Strategic Scientific Committee and the Board regarding business risks, development programs, and the relationship with SG Austria.
• Potentially seek a new framework for the relationship with SG Austria and its subsidiaries.
• Identify alternative approaches to expand the prodrug/activator technology for cancer treatment.
• Hire an additional person to work for the Chief Financial Officer to enable sufficient segregation of duties and improve management review controls.
• Apply for patent term extension on patents covering approved products, if eligible.
• Explore opportunities for Fast Track, Breakthrough Therapy, and Priority Review designations for product candidates.
• Potentially seek accelerated approval pathways for certain product candidates.
• Develop sales, marketing, and distribution capabilities, or license product candidates to third parties for commercialization.
• Continue to monitor IRS guidance and evaluate the impact of new tax laws, with certain provisions of The One Big Beautiful Bill Act of 2025 becoming effective in fiscal 2026.

Key Dates

Recommendation

The company reported a significant net income for FY2025, primarily driven by non-operating investment gains and fair value adjustments, rather than core operational success. The ongoing FDA clinical hold on its primary LAPC therapy, coupled with a strategic reevaluation of its relationship with key technology providers and a substantial decrease in cash and working capital, introduces considerable uncertainty and risk. While the company has made progress on some FDA requests and holds Orphan Drug designation, the path to commercialization remains long, expensive, and uncertain. The identified material weaknesses in internal controls and high dependence on external funding further warrant caution. A 'Hold' recommendation reflects the speculative nature of the investment, acknowledging the potential for future development but emphasizing the significant hurdles and risks that need to be overcome before a clear path to profitability is established.

Keywords

Biotechnology, Cancer Therapy, Cell-in-a-Box, Pancreatic Cancer, LAPC, CypCaps, FDA Clinical Hold, Cellular Encapsulation, Oncology, Drug Development, SEC Filing, 10-K, PharmaCyte Biotech, PMCB, Clinical Trials, Orphan Drug, Financial Reporting, Corporate Governance, Risk Management, Femasys, TNF Pharmaceuticals, Biologics, Healthcare Regulation, Intellectual Property